CN105233125A - Medicine for treating aplastic anemia and preparing method thereof - Google Patents
Medicine for treating aplastic anemia and preparing method thereof Download PDFInfo
- Publication number
- CN105233125A CN105233125A CN201510760625.2A CN201510760625A CN105233125A CN 105233125 A CN105233125 A CN 105233125A CN 201510760625 A CN201510760625 A CN 201510760625A CN 105233125 A CN105233125 A CN 105233125A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- aplastic anemia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicine for treating aplastic anemia and a preparing method thereof. The medicine is prepared from 20 parts to 30 parts of ginseng, 25 parts to 35 parts of astragalus membranaceus, 35 parts to 45 parts of pericarpium citri reticulatae, 35 parts to 45 parts of colla corii asini, 20 parts to 30 parts of carbonized hair, 25 parts to 35 parts of angelica sinensis, 7 parts to 13 parts of radix paeoniae alba, 35 parts to 45 parts of rehmannia glutinosa, 20 parts to 30 parts of medlar, 10 parts to 20 parts of salvia miltiorrhiza, 25 parts to 35 parts of asparagus cochinchinensis, 10 parts to 20 parts of schisandra chinensis, 10 parts to 20 parts of elecampane, 40 parts to 60 parts of lalang grass rhizomes, 40 parts to 60 parts of antlet glue, 10 parts to 20 parts of radix glycyrrhizae preparata, 10 parts to 20 parts of lotus seed pot carbon, 900 parts to 1,100 parts of bovine bone marrow, 45 parts to 50 parts of inonotus obliquus, 25 parts to 35 parts of hairyvein agrimony and 5 parts to 10 parts of fructus alpiniae oxyphyllae. The aplastic anemia cure rate is 94.6%, the effective rate is 98.2%, the intractable constipation cure rate is 71.1%, and the effective rate is 100%.
Description
Technical field
The present invention relates to a kind of Chinese medicine, specifically, relate to a kind of medicine for the treatment of aplastic anemia and preparation method thereof, belong to tcm field.
Background technology
Aplastic anemia is one group of syndrome of the marrow hematopoiesis function failure caused by many reasons.
Generally have chemical factor: arsenic, run quickly, lead poisoning; Medicine chloromycetin, suntomycinum, sulfamethoxazole, Xin Kefen, green promazine, phenobarbital, dipyrone; Pesticide intoxication: 3911,1059,1605 etc.; Physical factor: ionizing radiation, x-ray radiation, radioprotective etc.Generally show as anemia, hemorrhage, infect, have a high fever or low grade fever, and with weak on foot, the symptom such as dizzy.(hemolytic anemia, iron deficiency anemia, myleo anemia, granulocyte leukemia, thalassemia, leukemic lymphoblastoid is comprised in hematopathy ...) aplastic anemia and leukemia mortality account for 80%, acute aplastic anemia and leukemic mortality rate account for 95%, therefore aplastic anemia have the title of " cephaloma ", the title that leukemia has " leukemia ".
Aplastic anemia is generally divided into acute aplastic anemia (AAA) and chronic aplastic anemia (CAA), and the standard of acute aplastic anemia is morbidity urgency, anemia, severe infections and visceral hemorrhage.Routine blood test chemical examination is fast for hematochrome (HB) declines, Reticulocyte <1%, platelet (PLT) <2 ten thousand.Bone marrow smear three is that hematopoietic cell obviously reduces, and lymphsystem is high, and non-hematopoietic cell increases (lymphocyte, plasma cell, skein cell, mastocyte); Chronic aplastic anemia standard is: pancytopenia, and reticulocyte reduces, and forms three low height.Non-hematopoietic cell increases, and megalokaryocyte reduces.To be three be bone marrow smear or two be minimizing, and at least one position hypertrophy is bad, and non-hematopoietic cell increases, and megalokaryocyte obviously reduces, and evening, children redly increased.
In the treatment of aplastic anemia, doctor trained in Western medicine generally adopts hormone therapy to chronic aplastic anemia, adopts immunosuppressant therapy method to acute aplastic anemia; Obtained many experiences abroad with bone marrow transplantation therapy aplastic anemia, usually adopted the bone marrow of the identical person of German sister blood brother HLA, successfully thirsted for aplastic anemia to cure if transplanted, but bone marrow transplantation is still difficult to extensive use and costly at present.Western medical treatment aplastic anemia can only temporary transient symptom management, but is not the treatment means that patient seeks rehabilitation, and the toxic and side effects long duration of action of Western medicine, in human body, can cause great infringement to Liver and kidney.
Summary of the invention
The problem that invention will solve is for above deficiency, provides a kind of medicine for the treatment of aplastic anemia and preparation method thereof, adopts medicine of the present invention, has the advantage that effective percentage is high; And treatment obstipation has good result and relapse rate is low.
For solving above technical problem, the technical solution adopted in the present invention is: a kind of medicine for the treatment of aplastic anemia, it is characterized in that, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 20-30 part, Radix Astragali 25-35 part, Pericarpium Citri Reticulatae 35-45 part, Colla Corii Asini 35-45 part, Crinis Carbonisatus 20-30 part, Radix Angelicae Sinensis 25-35 part, Radix Paeoniae Alba 7-13 part, Radix Rehmanniae Preparata 35-45 part, Fructus Lycii 20-30 part, Radix Salviae Miltiorrhizae 10-20 part, Radix Asparagi 25-35 part, Fructus Schisandrae Chinensis 10-20 part, Radix Aucklandiae 10-20 part, Rhizoma Imperatae 40-60 part, Colla cornus cervi 40-60 part, Radix Glycyrrhizae Preparata 10-20 part, charred Receptaculum Nelumbinis 10-20 part, Medulla Bovis seu Bubali 900-1100 part, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 45-50 part, Herba Agrimoniae 25-35 part and Fructus Alpiniae Oxyphyllae 5-10 part.
A kind of prioritization scheme, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 25 parts, the Radix Astragali 30 parts, Pericarpium Citri Reticulatae 40 parts, 40 parts, Colla Corii Asini, Crinis Carbonisatus 25 parts, Radix Angelicae Sinensis 30 parts, the Radix Paeoniae Alba 10 parts, 40 parts, Radix Rehmanniae Preparata, Fructus Lycii 25 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Asparagi 30 parts, Fructus Schisandrae Chinensis 15 parts, the Radix Aucklandiae 15 parts, Rhizoma Imperatae 50 parts, Colla cornus cervi 50 parts, Radix Glycyrrhizae Preparata 15 parts, charred Receptaculum Nelumbinis 15 parts, Medulla Bovis seu Bubali 1000 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 47 parts, Herba Agrimoniae 30 parts and Fructus Alpiniae Oxyphyllae 7 parts.
Based on a kind of medicine for the treatment of aplastic anemia, its preparation method comprises the following steps:
1) described raw material is got according to weight portion;
2) Radix Ginseng, Radix Angelicae Sinensis, Medulla Bovis seu Bubali, Colla cornus cervi, Colla Corii Asini are ground into fine powder, sieve, mixing;
3) all the other raw materials pure water of 10 times amount 80 DEG C is infiltrated 60 minutes, then soak by water twice, each 2 hours, filter, merging filtrate, be concentrated into the clear paste of relative density 1.30 ~ 1.35 at 60 DEG C, add above-mentioned fine powder, mixing, dry, pulverize, granulate, encapsulated, to obtain final product.
The present invention adopts above technical scheme, compared with prior art, has the following advantages: in above medicine, and monarch compatibility is proper, synergism, and aplastic anemia cure rate reaches 94.6%, effective percentage 98.2%; Obstipation cure rate reaches 71.1%, and effective percentage reaches 100%.
Below in conjunction with embodiment, the invention will be further described.
Detailed description of the invention
Embodiment 1, the medicine for the treatment of aplastic anemia, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 20 parts, the Radix Astragali 35 parts, Pericarpium Citri Reticulatae 35 parts, 45 parts, Colla Corii Asini, Crinis Carbonisatus 20 parts, Radix Angelicae Sinensis 25 parts, the Radix Paeoniae Alba 7 parts, 45 parts, Radix Rehmanniae Preparata, Fructus Lycii 20 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Asparagi 35 parts, Fructus Schisandrae Chinensis 10 parts, the Radix Aucklandiae 20 parts, Rhizoma Imperatae 40 parts, Colla cornus cervi 60 parts, Radix Glycyrrhizae Preparata 10 parts, charred Receptaculum Nelumbinis 20 parts, Medulla Bovis seu Bubali 900 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 45 parts, Herba Agrimoniae 25 parts and Fructus Alpiniae Oxyphyllae 10 parts.
Embodiment 2, the medicine for the treatment of aplastic anemia, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 30 parts, the Radix Astragali 25 parts, Pericarpium Citri Reticulatae 45 parts, 35 parts, Colla Corii Asini, Crinis Carbonisatus 30 parts, Radix Angelicae Sinensis 35 parts, the Radix Paeoniae Alba 13 parts, 35 parts, Radix Rehmanniae Preparata, Fructus Lycii 30 parts, Radix Salviae Miltiorrhizae 20 parts, Radix Asparagi 25 parts, Fructus Schisandrae Chinensis 20 parts, the Radix Aucklandiae 10 parts, Rhizoma Imperatae 60 parts, Colla cornus cervi 40 parts, Radix Glycyrrhizae Preparata 20 parts, charred Receptaculum Nelumbinis 10 parts, Medulla Bovis seu Bubali 1100 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 50 parts, Herba Agrimoniae 35 parts and Fructus Alpiniae Oxyphyllae 5 parts.
Embodiment 3, the medicine for the treatment of aplastic anemia, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 25 parts, the Radix Astragali 30 parts, Pericarpium Citri Reticulatae 40 parts, 40 parts, Colla Corii Asini, Crinis Carbonisatus 25 parts, Radix Angelicae Sinensis 30 parts, the Radix Paeoniae Alba 10 parts, 40 parts, Radix Rehmanniae Preparata, Fructus Lycii 25 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Asparagi 30 parts, Fructus Schisandrae Chinensis 15 parts, the Radix Aucklandiae 15 parts, Rhizoma Imperatae 50 parts, Colla cornus cervi 50 parts, Radix Glycyrrhizae Preparata 15 parts, charred Receptaculum Nelumbinis 15 parts, Medulla Bovis seu Bubali 1000 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 47 parts, Herba Agrimoniae 30 parts and Fructus Alpiniae Oxyphyllae 7 parts.
Embodiment 4, the medicine for the treatment of aplastic anemia, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 22 parts, the Radix Astragali 33 parts, Pericarpium Citri Reticulatae 38 parts, 43 parts, Colla Corii Asini, Crinis Carbonisatus 22 parts, Radix Angelicae Sinensis 27 parts, the Radix Paeoniae Alba 8 parts, 38 parts, Radix Rehmanniae Preparata, Fructus Lycii 24 parts, Radix Salviae Miltiorrhizae 17 parts, Radix Asparagi 33 parts, Fructus Schisandrae Chinensis 17 parts, the Radix Aucklandiae 18 parts, Rhizoma Imperatae 46 parts, Colla cornus cervi 56 parts, Radix Glycyrrhizae Preparata 13 parts, charred Receptaculum Nelumbinis 12 parts, Medulla Bovis seu Bubali 965 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 46 parts, Herba Agrimoniae 28 parts and Fructus Alpiniae Oxyphyllae 6 parts.
Embodiment 5, the medicine for the treatment of aplastic anemia, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 27 parts, the Radix Astragali 28 parts, Pericarpium Citri Reticulatae 43 parts, 37 parts, Colla Corii Asini, Crinis Carbonisatus 28 parts, Radix Angelicae Sinensis 33 parts, the Radix Paeoniae Alba 11 parts, 42 parts, Radix Rehmanniae Preparata, Fructus Lycii 28 parts, Radix Salviae Miltiorrhizae 13 parts, Radix Asparagi 27 parts, Fructus Schisandrae Chinensis 13 parts, the Radix Aucklandiae 13 parts, Rhizoma Imperatae 55 parts, Colla cornus cervi 45 parts, Radix Glycyrrhizae Preparata 17 parts, charred Receptaculum Nelumbinis 18 parts, Medulla Bovis seu Bubali 1050 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 49 parts, Herba Agrimoniae 33 parts and Fructus Alpiniae Oxyphyllae 9 parts.
The medicine of above embodiment is prepared according to following steps respectively:
1) described raw material is got according to weight portion;
2) Radix Ginseng, Radix Angelicae Sinensis, Medulla Bovis seu Bubali, Colla cornus cervi, Colla Corii Asini ground spice are broken into fine powder, sieve, mixing;
3) all the other raw materials pure water of 10 times amount 80 DEG C is infiltrated 60 minutes, then soak by water twice, each 2 hours, filter, merging filtrate, be concentrated into the clear paste of relative density 1.30 ~ 1.35 at 60 DEG C, add above-mentioned fine powder, mixing, dry, pulverize, granulate, encapsulated, to obtain final product.
Every dress 0.5g, oral, 3 times on the one, one time 2, within 30 days, be a course for the treatment of.
Show through contrast test, medicine prepared by above embodiment all has reasonable effect to treatment aplastic anemia, and effective percentage reaches 89.63%-98.2%, and wherein, the therapeutic effect of embodiment 3 gained medicine is best, and below test adopts embodiment 3 gained medicine.
Case is chosen by national Teaching Materials at College level " internal medicine " the 7th edition diagnostic criteria about aplastic anemia: 1, pancytopenia, and reticulocyte percent is less than 0.01, and percentage of lymphocyte increases; 2, general without liver, splenomegaly; 3, bone marrow multiple location hypoplasia, hematopoietic cell reduces, and non-hematopoietic cell ratio increases; 4, the disease of pancytopenia is caused except; 5, general anti-anemia action is failed to respond to any medical treatment.
All meet this diagnostic criteria randomly draw the routine Patients with Aplastic Anemia of Patients with Aplastic Anemia 110, be divided into two groups at random.One group of 56 example is treatment group, wherein man 31 example, female 25 example; Age 16-68 year, average 36.1 years old; The course of disease is the shortest 3 years, the longest 23 years, average 13.3, adopts the embodiment of the present invention 3 gained medicine and using method.Another group 54 examples are matched group, wherein man 28 example, female 26 example; Age 14.3-63 year, average 35.4 years old; The course of disease is the shortest 3.5 years, the longest 18 years, average 12.4, applies the treatment of traditional anti-regeneration aplastic anemia as hemopoietic medicine, immunosuppressive drug, Hemopoietic factor symptomatic treatment.Age of two groups, sex, the course of disease compare there was no significant difference, have comparability.
Treatments period does not use other drug to treat, and checks routine blood test after treatment.
Criterion of therapeutical effect:
Cure: anemia and bleeding disappear; Hemoglobin reaches 120g/L(man) or 110g/L(female), leukocyte reaches 4*10
9/ L, platelet reaches 100*10
9/ L.
Effective: anemia and bleeding disappear; Hemoglobin reaches 110g/L(man) or 100g/L(female), leukocyte reaches 3.5*10
9/ L, platelet has to a certain degree to be increased, and follows up a case by regular visits to 3 months stable disease or progress.
Invalid: through fully treating, symptom, hemogram do not reach obvious progress.
After a course for the treatment of, check routine blood test: have 47 people to cure in treatment group, 8 people are effective, invalid 1 people, and cure rate reaches 83.9%; In contrast groups, 20 people cure, and 23 people are effective, invalid 11 people, cure rate 37%.
After three courses for the treatment of, have 53 people to cure in treatment group, 2 people are effective, invalid 1 people, and cure rate reaches 94.6%, effective percentage 98.2%; In contrast groups, 24 people cure, and 19 people are effective, invalid 11 people, cure rate 44.4%, effective percentage 79.6%.
In practice, in above aplastic anemia patient, some patients suffers from obstipation, and this part patient is except aplastic anemia improves, and unexpected discovery also has effect to obstipation, and take medicine of the present invention and namely tell on after one week, especially more than 60 years old patient outcome is good.
For verifying its curative effect, choose obstipation patient 86 example, all cases all meets national Teaching Materials at College level " internal medicine " the 8th edition constipation diagnostic criteria.
Random selecting 45 example as treatment group, wherein man 22 example, female 23 example, the age between 60 ~ 76 years old, 66.5 years old mean age, the course of disease 6 ~ 16 years; Wherein, 3 days stool, 1 time 18 example, 4 days stool, 1 time 14 example, more than 5 days stool, 1 time 13 example.
Random selecting 41 example as a control group, adopt conventional medicament treat, wherein man 25 example, female 16 example, the age between 62 ~ 74 years old, 65.2 years old mean age, the course of disease 6.5 ~ 13.5 years.3 days stool, 1 time 13 example, 4 days stool, 1 time 11 example, more than 5 days stool, 1 time 17 example.
Test method
Treatment group adopts embodiment 3 gained medicine.
Matched group takes each 2 of bisacodyl enteric coatel tablets (traditional Chinese medicines accurate word H37022712,2010-08-23, Jinan Heng Ji pharmaceutical Co. Ltd), and 1 time on the one, every sheet 5mg, full wafer is swallowed.
Within seven days, be a course for the treatment of, continuous two courses for the treatment of.
At whole treatments period, observe the untoward reaction of patient, untoward reaction refers to discomfort caused by drug administration or pathological changes.
Curative effect judging standard
Recovery from illness: constipation symptom disappears completely, stool is completely normal, and defecation is more unobstructed, follows up a case by regular visits to and does not recur half a year.
Effective: defecation 1 time in two days, just matter turns profit, and defecation is unobstructed, in a short time without recurrence.
Effective: defecation 1 time in 3 days, just matter turns profit, and defecation owes unobstructed.
Invalid: symptom is without improvement.
After the course for the treatment of, fully recover in treatment group 27 people, effective 11 people, effective 7 people, and number that is invalid, untoward reaction is zero, and cure rate reaches 60%, and total effective rate reaches 100%; Fully recover in contrast groups 11 people, effective 15 people, effective 6 people, invalid 6 people, and untoward reaction 3 people, cure rate reaches 48.8%, and total effective rate reaches 78%.
After two courses for the treatment of, fully recover in treatment group 32 people, effective 8 people, effective 5 people, and number that is invalid, untoward reaction is zero, and cure rate reaches 71.1%; Contrast groups does not have significant change.
Effect of follow-up visit by telephone, after 1 year, treatment group has 1 people's recurrence, and contrast groups has 8 people's recurrences.
Adopt the constipation of embodiment of the present invention gained Drug therapy, effective percentage reaches 100%, and do not observe obvious untoward reaction at whole treatments period, following up a case by regular visits to of lasting half a year is carried out to patient, only find the sign of an example recurrence, compared with two groups of contrast groups, have the significance difference opposite sex (P < 0.01), treatment group is better than matched group.
The above is the citing of best mode for carrying out the invention, and the part wherein do not addressed in detail is the common practise of those of ordinary skill in the art.Protection scope of the present invention is as the criterion with the content of claim, and any equivalent transformation carried out based on technology enlightenment of the present invention, also within protection scope of the present invention.
Claims (3)
1. treat the medicine of aplastic anemia for one kind, it is characterized in that, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 20-30 part, Radix Astragali 25-35 part, Pericarpium Citri Reticulatae 35-45 part, Colla Corii Asini 35-45 part, Crinis Carbonisatus 20-30 part, Radix Angelicae Sinensis 25-35 part, Radix Paeoniae Alba 7-13 part, Radix Rehmanniae Preparata 35-45 part, Fructus Lycii 20-30 part, Radix Salviae Miltiorrhizae 10-20 part, Radix Asparagi 25-35 part, Fructus Schisandrae Chinensis 10-20 part, Radix Aucklandiae 10-20 part, Rhizoma Imperatae 40-60 part, Colla cornus cervi 40-60 part, Radix Glycyrrhizae Preparata 10-20 part, charred Receptaculum Nelumbinis 10-20 part, Medulla Bovis seu Bubali 900-1100 part, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 45-50 part, Herba Agrimoniae 25-35 part and Fructus Alpiniae Oxyphyllae 5-10 part.
2. a kind of medicine for the treatment of aplastic anemia as claimed in claim 1, it is characterized in that, its curative effect composition comprises the raw material of following weight portion: Radix Ginseng 25 parts, the Radix Astragali 30 parts, Pericarpium Citri Reticulatae 40 parts, 40 parts, Colla Corii Asini, Crinis Carbonisatus 25 parts, Radix Angelicae Sinensis 30 parts, the Radix Paeoniae Alba 10 parts, 40 parts, Radix Rehmanniae Preparata, Fructus Lycii 25 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Asparagi 30 parts, Fructus Schisandrae Chinensis 15 parts, the Radix Aucklandiae 15 parts, Rhizoma Imperatae 50 parts, Colla cornus cervi 50 parts, Radix Glycyrrhizae Preparata 15 parts, charred Receptaculum Nelumbinis 15 parts, Medulla Bovis seu Bubali 1000 parts, Pyropolyporus fomentarius (L.ex Fr.) Teng Ganoderma 47 parts, Herba Agrimoniae 30 parts and Fructus Alpiniae Oxyphyllae 7 parts.
3. a kind of preparation method for the treatment of the medicine of aplastic anemia as claimed in claim 1 or 2, it is characterized in that, described preparation method comprises the following steps:
1) described raw material is got according to weight portion;
2) Radix Ginseng, Radix Angelicae Sinensis, Medulla Bovis seu Bubali, Colla cornus cervi, Colla Corii Asini are ground into fine powder, sieve, mixing;
3) all the other raw materials pure water of 10 times amount 80 DEG C is infiltrated 60 minutes, then soak by water twice, each 2 hours, filter, merging filtrate, be concentrated into the clear paste of relative density 1.30 ~ 1.35 at 60 DEG C, add above-mentioned fine powder, mixing, dry, pulverize, granulate, encapsulated, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510760625.2A CN105233125A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating aplastic anemia and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510760625.2A CN105233125A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating aplastic anemia and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105233125A true CN105233125A (en) | 2016-01-13 |
Family
ID=55031118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510760625.2A Pending CN105233125A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating aplastic anemia and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105233125A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634213A (en) * | 2003-12-27 | 2005-07-06 | 钟起哲 | Chinese medicinal formulation for hematogenesis |
| CN103690875A (en) * | 2013-12-29 | 2014-04-02 | 孙斌 | Traditional Chinese medicinal preparation for treating aplastic anemia |
-
2015
- 2015-11-10 CN CN201510760625.2A patent/CN105233125A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634213A (en) * | 2003-12-27 | 2005-07-06 | 钟起哲 | Chinese medicinal formulation for hematogenesis |
| CN103690875A (en) * | 2013-12-29 | 2014-04-02 | 孙斌 | Traditional Chinese medicinal preparation for treating aplastic anemia |
Non-Patent Citations (1)
| Title |
|---|
| 刘天福等: "中西医结合治疗再生障碍性贫血58例临床疗效分析", 《广东医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1188159C (en) | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn | |
| CN104666951A (en) | Traditional Chinese medicine composition for treating parturient paresis puerperal fever | |
| CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN101130054A (en) | Traditional Chinese medicine for treating essential resistance of turbid phlegm type vertigo | |
| CN105012893A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN102861199A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and preparation method | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN1943756A (en) | A Chinese traditional medicinal composite used for treatment of hypertension and its preparation method | |
| CN101249207A (en) | Medicament prescription for treating coronary heart disease | |
| CN105233125A (en) | Medicine for treating aplastic anemia and preparing method thereof | |
| CN103083559A (en) | Novel preparation method and application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage | |
| CN103055289B (en) | Traditional Chinese medicine composition for curing malignant lymphoma and preparation method thereof | |
| CN102671078B (en) | Medicine composition for curing myelofibrosis and hepatofibrosis and preparation method of medicine composition | |
| CN101461925A (en) | Medicament composition for treating hepatopathy and preparation method thereof | |
| CN109771632A (en) | A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN103860869A (en) | Traditional Chinese medicine for treating gestational hypertension | |
| CN103736051A (en) | Hemangioma nursing medicament and preparation method thereof | |
| CN103055029A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and preparation method thereof | |
| CN107019743A (en) | A kind of Chinese herbal feed additive for preventing and treating animal viral disease and preparation method thereof | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN101444572A (en) | Pharmaceutical composition for treating leukaemia | |
| CN101757511A (en) | Medicine composition for treating acute and chronic neutrophilic leukemia and preparation method thereof | |
| CN105327279A (en) | Traditional Chinese medicinal composition for treating leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160113 |